Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study

BACKGROUND: Neurofibromatosis type 1 (NF-1) frequently leads to inoperable, symptomatic plexiform neurofibromas (PNs) with limited therapeutic options. This study evaluates the real-world activity and safety of the MEK inhibitor trametinib in pediatric NF-1 patients with inoperable PNs in France. METHODS: We analyzed pediatric patients enrolled in the SACHA-France study (NCT04477681) who received trametinib for inoperable PNs between 01/2020 and 01/2026. Antitumor activity was evaluated by treating physicians using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Clinical benefit data were collected retrospectively. RESULTS: Twenty-three patients (median age: 6 years [range: 0-17]) were included. Clinical benefit occurred in 87% (20/23), mainly through pain reduction (86% of symptomatic patients, 12/14). RECIST assessment showed partial response in 4% (1/23), stable disease in 87% (20/23), and progression in 9% (2/23). AEs occurred in 96% of patients, predominantly cutaneous (96%) and Grade 1-2. Four Grade 3 AEs were reported (osteitis, paronychia [n = 2], elevated creatine kinase), prompting discontinuation in 2 cases. Median treatment duration was 33 months [range: 1-58]. Treatment was discontinued in seven patients for prolonged stable disease, four for disease progression (two clinical, two radiological), two for severe AEs, and one for poor adherence. Nine patients remained on treatment at cutoff. CONCLUSION: Trametinib provided notable clinical benefit and disease stabilization in pediatric NF-1-associated PNs, despite limited RECIST-defined tumor shrinkage. The safety profile was manageable and consistent with known data. Comparative studies with other MEK inhibitors are warranted to optimize treatment strategies.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2026-11-17
DOI
https://doi.org/10.1002/1545-5017.70820
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study

Isabelle Aerts, Yves Réguerre, Camille Khanfar, Pablo Berlanga et al.
2 links
Pediatric Blood & Cancer
Neurofibromatosis and Schwannoma Cases
article

Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study

Isabelle Aerts, Yves Réguerre, Camille Khanfar, Pablo Berlanga, Cécile Faure‐Conter, Anne Pagnier, Stéphane Ducassou, Nicolás André, François Sevrin, Gilles Vassal, Liana Carausu, Claire Freyçon, Samuel D. Abbou, Lee Aymar Ndounga‐Diakou, Pierre Leblond, Natacha Entz-Werle, Clara Rigaud Vanderkelen
article en

Abstract

BACKGROUND: Neurofibromatosis type 1 (NF-1) frequently leads to inoperable, symptomatic plexiform neurofibromas (PNs) with limited therapeutic options. This study evaluates the real-world activity and safety of the MEK inhibitor trametinib in pediatric NF-1 patients with inoperable PNs in France. METHODS: We analyzed pediatric patients enrolled in the SACHA-France study (NCT04477681) who received trametinib for inoperable PNs between 01/2020 and 01/2026. Antitumor activity was evaluated by treating physicians using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Clinical benefit data were collected retrospectively. RESULTS: Twenty-three patients (median age: 6 years [range: 0-17]) were included. Clinical benefit occurred in 87% (20/23), mainly through pain reduction (86% of symptomatic patients, 12/14). RECIST assessment showed partial response in 4% (1/23), stable disease in 87% (20/23), and progression in 9% (2/23). AEs occurred in 96% of patients, predominantly cutaneous (96%) and Grade 1-2. Four Grade 3 AEs were reported (osteitis, paronychia [n = 2], elevated creatine kinase), prompting discontinuation in 2 cases. Median treatment duration was 33 months [range: 1-58]. Treatment was discontinued in seven patients for prolonged stable disease, four for disease progression (two clinical, two radiological), two for severe AEs, and one for poor adherence. Nine patients remained on treatment at cutoff. CONCLUSION: Trametinib provided notable clinical benefit and disease stabilization in pediatric NF-1-associated PNs, despite limited RECIST-defined tumor shrinkage. The safety profile was manageable and consistent with known data. Comparative studies with other MEK inhibitors are warranted to optimize treatment strategies.

Pediatric Blood & Cancer
Centre National de la Recherche Scientifique (FR), Inserm (FR), Aix-Marseille Université (FR), University of Reunion Island (RE), Université Paris Sciences et Lettres (FR), Université Paris-Saclay (FR), Centre Hospitalier Universitaire de Grenoble (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Bordeaux (FR), Assistance Publique Hôpitaux de Marseille (FR), Centre Hospitalier Universitaire de La Réunion (RE), Institut d’Hématologie et d’Oncologie Pédiatrique (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Centre Léon Bérard (FR), Centre Oscar Lambret (FR), Centre Hospitalier Régional Universitaire de Brest (FR), Centre de Recherche en Cancérologie de Marseille (FR), Hôpitaux Universitaires de Strasbourg (FR), Centre Hospitalier Saint-Denis (FR), Hôpital de la Timone (FR), Observatoire des Sciences de l'Univers de la Réunion (RE), Université Paris 8 (FR), Institut Curie (FR)
Good health and well-being
Neurofibromatosis and Schwannoma Cases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon